Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Danske Bank and SEB in relation to Raketech’s listing on Nasdaq First North Premier
Mandate

Vinge advises Danske Bank and SEB in relation to Raketech’s listing on Nasdaq First North Premier

June 20, 2018 Capital Markets and Public M&A

Vinge advises Danske Bank A/S, Danmark, Sverige Filial and Skandinaviska Enskilda Banken (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of Raketech Group Holding plc – a marketing actor whose primary business involves using its online products to influence iGaming market users who are interested in sports and gambling and to guide them towards the best gambling services – on Nasdaq First North Premier. 

A prospectus was published on 18 June 2018 and the first day of trading on Nasdaq First North Premier is 29 June 2018. The total value of the offering amounts to between approx. SEK 530-550 million, assuming that the over-allotment option is exercised in full.
 
Vinge’s team consist mainly of David Andersson, Amanda Knutsson, Rikard Lindahl and Stephanie Stiernstedt.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026